ALK protein expression and gene copy number alterations in triple-negative breast cancer: Clinical implications.
Anaplastic lymphoma kinase protein is expressed in about one in five triple-negative breast cancers.
ALK protein expression and gene copy number alterations in triple-negative breast cancer: Clinical implications.
Anaplastic lymphoma kinase (anaplastic lymphoma kinase) is a well-established oncogenic driver in non-small cell lung cancer (non-small cell lung cancer), but its role in triple-negative breast cancer (triple-negative breast cancer) remains largely unexplored.
In this study, we examined the expression and gene status of anaplastic lymphoma kinase in 208 triple-negative breast cancer cases using immunohistochemistry (immunohistochemistry) and fluorescence in situ hybridization (FISH).
Among the 156 basal-like breast carcinoma (basal-like breast carcinoma) cases, anaplastic lymphoma kinase presented three distinct localization patterns: diffuse cytoplasmic granular, cytoplasmic/membranous, and cytoplasmic/nuclear.
Anaplastic lymphoma kinase gene copy number abnormalities were detected in 16.8% of cases, with a higher prevalence in p53-mutant and high Ki67 expression tumors.
Our findings highlight the importance of anaplastic lymphoma kinase as a potential therapeutic target in triple-negative breast cancer, emphasizing the need for further investigation into its clinical significance.